Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | MGLL | Q99685 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | CKS1B | P61024 | 1/20 | 0.46 |
| ▸ | SKP1 | P63208 | 1/20 | 0.46 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14128435 | 0.89 | GPR119 (0.50) | GLSLMNAGAAATMGPR119 | |
| SCHEMBL12371643 | 0.88 | MEN1 (0.56) | GLSKMT2AMEN1MGLLNPC1 | |
| SCHEMBL5083759 | 0.88 | ALDH1A1 (0.61) | GLSLMNAATMGPR119KMT2A | |
| SCHEMBL5183732 | 0.88 | MEN1 (0.49) | GLSLMNAATMGPR119KMT2A | |
| SCHEMBL19668434 | 0.87 | ALDH1A1 (0.55) | GLSLMNAGPR119KMT2AMEN1 | |
| SCHEMBL19668491 | 0.86 | CYP3A4 (0.47) | GLSLMNAGAAATMGPR119 | |
| SCHEMBL29508239 | 0.86 | CYP3A4 (0.47) | GLSLMNAGAAATMGPR119 | |
| SCHEMBL29363322 | 0.86 | CYP3A4 (0.59) | GLSGPR119MGLLCYP3A4CYP3A5 | |
| SCHEMBL19668681 | 0.86 | CYP3A4 (0.59) | GLSGPR119MGLLCYP3A4CYP3A5 | |
| SCHEMBL13476475 | 0.86 | P2RX3 (0.48) | GLSLMNAATMGPR119MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 192 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107097-A1 | SELF-IMMOLATIVE LINKERS AND CONJUGATES THEREOF | ENLAZA THERAPEUTICS, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| US-12630808-B2 | Modified archaeal family b polymerases | Singular Genomics Systems, Inc. (US) | 2026-05-19 | — | — | US | disclosed |
| US-20260125660-A1 | MODIFIED ARCHAEAL FAMILY B POLYMERASES | SINGULAR GENOMICS SYSTEMS INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260091017-A1 | TREATMENTS FOR INFLAMMATION | AUCKLAND UNISERVICES LTD (NZ) | 2026-04-02 | — | — | US | disclosed |
| US-20260085299-A1 | ENGINEERED PYROCOCCUS ENZYMES AND USES THEREOF | SINGULAR GENOMICS SYSTEMS INC (US) | 2026-03-26 | — | — | US | disclosed |
| US-12564644-B2 | Cyclodextrin complexes of specialized proresolving mediators | THETIS PHARMACEUTICALS LLC (US) | 2026-03-03 | — | — | US | disclosed |
| EP-4677087-A1 | NOVEL TREATMENTS FOR OCULAR DISORDERS | Glaukos Corporation (US) | 2026-01-14 | — | — | EP | disclosed |
| US-20250381270-A1 | ISOLATING ACTIVE T-CELL CARS FROM BULK TRANSDUCED HUMAN T-CELLS | UNIV CALIFORNIA (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250353926-A1 | CROSSLINKING MULTISPECIFIC ANTIBODIES | ENLAZA THERAPEUTICS INC (US) | 2025-11-20 | — | — | US | disclosed |
| US-20250352508-A1 | PREVENTION AND TREATMENT OF POST-ACUTE INFECTION SYNDROMES | INFLAMMX THERAPEUTICS INC (US) | 2025-11-20 | — | — | US | disclosed |
| US-20040176405-A1 | Methods and compounds for inhibitting MRP1 | KROIN JULIAN (US) | 2004-09-09 | — | — | US | disclosed |
| US-20040116699-A1 | Melanocortin receptor agonists | ELI LILLY AND COMPANY | 2004-06-17 | — | — | US | disclosed |
| US-6743794-B2 | MULTIDRUG RESISTANCE PROTEIN; CANCER; 3-(9-CHLORO-3-METHYL-4-OXO-5H-ISOXAZOLO(4,3-C)QUINOLIN-5-YL)) CYCLOHEXYL)-2-PIPERIDYLACETAMIDE | ELI LILLY AND COMPANY | 2004-06-01 | — | — | US | disclosed |
| EP-1358163-A1 | MELANOCORTIN RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2003-11-05 | — | — | EP | disclosed |
| US-20030153556-A1 | Piperazine and homopiperazine compounds | MILLENNIUM PHARMACEUTICALS, INC. | 2003-08-14 | — | — | US | disclosed |
| US-20030100576-A1 | Methods and compounds for inhibiting mrp1 | ELI LILLY AND COMPANY | 2003-05-29 | — | — | US | disclosed |
| WO-2003022214-A2 | PIPERAZINE AND HOMOPIPERAZINE COMPOUNDS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2003-03-20 | — | — | WO | disclosed |
| EP-1250340-A1 | METHODS AND COMPOUNDS FOR INHIBITING MRP1 | ELI LILLY AND COMPANY (US) | 2002-10-23 | — | — | EP | disclosed |
| WO-2002059095-A1 | MELANOCORTIN RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2002-08-01 | — | — | WO | disclosed |
| WO-2001046199-A1 | METHODS AND COMPOUNDS FOR INHIBITING MRP1 | ELI LILLY AND COMPANY (US) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260091017-A1 | TREATMENTS FOR INFLAMMATION | P2RX7, NLRP3, PYCARD | GLS 3210/4885LMNA 880/4885GAA 4329/4885 |
| US-20250352508-A1 | PREVENTION AND TREATMENT OF POST-ACUTE INFECTION SYNDROMES | NLRP3, GJA1, PYCARD | GLS 1719/4885LMNA 40/4885GAA 3430/4885 |
| US-12630808-B2 | Modified archaeal family b polymerases | SSU72, POLB, POLQ | GLS 226/4885LMNA 547/4885GAA 3345/4885 |
| US-20030153556-A1 | Piperazine and homopiperazine compounds | HAMP, MPL, F2 | GLS 1814/4885LMNA 4352/4885GAA 4771/4885 |
| US-20250381270-A1 | ISOLATING ACTIVE T-CELL CARS FROM BULK TRANSDUCED HUMAN T-CELLS | PBK, CD4, ICOS | GLS 3670/4885LMNA 3021/4885GAA 1458/4885 |
| US-20250353926-A1 | CROSSLINKING MULTISPECIFIC ANTIBODIES | FCGR3B, FCGR2A, CD22 | GLS 1050/4885LMNA 3532/4885GAA 898/4885 |
| US-20040176405-A1 | Methods and compounds for inhibitting MRP1 | ABCC1, ABCB11, ABCB1 | GLS 118/4885LMNA 2547/4885GAA 763/4885 |
| US-20260085299-A1 | ENGINEERED PYROCOCCUS ENZYMES AND USES THEREOF | POLB, POLM, POLRMT | GLS 309/4885LMNA 1840/4885GAA 3036/4885 |
| US-20030100576-A1 | Methods and compounds for inhibiting mrp1 | ABCC1, ABCB11, ABCB1 | GLS 96/4885LMNA 2226/4885GAA 806/4885 |
| US-20260125660-A1 | MODIFIED ARCHAEAL FAMILY B POLYMERASES | DNMT3A, POLB, POLM | GLS 246/4885LMNA 1601/4885GAA 3263/4885 |
| US-12564644-B2 | Cyclodextrin complexes of specialized proresolving mediators | ALOX15, ALOX12, PTGES | GLS 3937/4885LMNA 1120/4885GAA 4780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.